新抗原T细胞受体基因治疗胰腺癌
一例进展期转移性胰腺癌患者接受单次输注16.2×10^9个自体T细胞,这些T细胞经基因工程改造克隆表达两种同种异体HLA-C*08:02限制性T细胞受体,靶向肿瘤表达的突变KRAS G12D;患者内脏转移灶消退(总部分缓解72%),缓解持续至6个月,改造后T细胞占循环外周血T细胞2%以上。
要点
- 靶向KRAS G12D的TCR基因治疗使转移性胰腺癌患者内脏转移灶客观消退。
- 单次输注16.2×10^9个工程化T细胞后总部分缓解为72%,缓解持续至6个月。
- 输注6个月后工程化T细胞占循环外周血T细胞2%以上。
核心结论
- 在该患者中,靶向KRAS G12D驱动突变的TCR基因治疗介导了转移性胰腺癌的客观消退。
研究设计与样本
- 一例进展期转移性胰腺癌患者接受单次输注16.2×10^9个自体T细胞,这些细胞经基因工程改造克隆表达两种同种异体HLA-C*08:02限制性TCR,靶向肿瘤表达的突变KRAS G12D。
主要发现
- 患者内脏转移灶消退,依据实体瘤疗效评价标准1.1版总部分缓解为72%。
- 缓解在6个月时仍在持续。
- 细胞输注6个月后,工程化T细胞占全部循环外周血T细胞的2%以上。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A patient with progressive metastatic pancreatic cancer was treated with a single infusion of 16.2×109 autologous T cells that had been genetically engineered to clonally express two allogeneic HLA-C*08:02-restricted T-cell receptors (TCRs) targeting mutant KRAS G12D expressed by the tumors. The patient had regression of visceral metastases (overall partial response of 72% according to the Response Evaluation Criteria in Solid Tumors, version 1.1); the response was ongoing at 6 months. The engineered T cells constituted more than 2% of all the circulating peripheral-blood T cells 6 months after the cell transfer. In this patient, TCR gene therapy targeting the KRAS G12D driver mutation mediated the objective regression of metastatic pancreatic cancer. (Funded by the Providence Portland Medical Foundation.).
引用
- Leidner R, Sanjuan Silva N, Huang H, et al. Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. N Engl J Med. 2022. PMID: 35648703. doi:10.1056/NEJMoa2119662
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。